Avience Biomedicals Ltd
Wed 16/09/2026,15:58:50 | NSE : AVIENCE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 340.10
Previous Close
₹ 349.60
Volume
37200
Mkt Cap ( ₹ Cr)
₹ 185.09
High
₹ 345.95
Low
₹ 325.00
52 Week High
₹ 414.95
52 Week Low
₹ 222.00
Book Value Per Share
₹ 59.92
Dividend Yield
₹ 0.00
Face Value
₹₹10.00
What's Your Call?
Collective community sentiment on Avience Biomedicals Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
337.45
600
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
600
Option Chain
Analyzes market sentiment, predicts Avience Biomedicals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Avience Biomedicals - Copy of Newspaper Publication
-
Avience Biomedicals - Updates
-
Avience Biomedicals - Shareholders meeting
-
Avience Biomedicals - Updates
-
Avience Biomedicals - Copy of Newspaper Publication
-
Avience Biomedicals - Outcome of Board Meeting
-
Avience Biomedicals - Outcome of Board Meeting
-
Avience Biomedicals - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Avience Biomedicals - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
-
Avience Biomedicals - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Avience Biomedicals - Analysts/Institutional Investor Meet/Con. Call Updates
-
Avience Biomedicals - Updates
-
Avience Biomedicals - Analysts/Institutional Investor Meet/Con. Call Updates
-
Avience Biomedicals - Investor Presentation
-
Avience Biomedicals - Analysts/Institutional Investor Meet/Con. Call Updates
-
Avience Biomedicals has submitted to BSE the Shareholding Pattern for the Period Ended June 24, 2026
-
Avience Biomedicals - Outcome of Board Meeting
-
Avience Biomedicals Ltd. debuts with 90.00% premium at Rs 395.20
Key fundamentals
Evaluate the intrinsic value of Avience Biomedicals Ltd stockÂ
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 46.1897 | 34.2698 | 13.7845 | 6.7266 | 5.2804 |
| Liabilities | 46.1897 | 34.2698 | 13.7845 | 6.7266 | 5.2804 |
| Equity | 4.0313 | 4.0313 | 3.2845 | 3.2845 | 2.0345 |
| Gross Profit | 10.9023 | 7.6519 | 3.1493 | 1.425 | 1.218 |
| Net Profit | 6.7333 | 5.135 | 1.9838 | 0.7078 | 0.7125 |
| Cash From Operating Activities | 5.9733 | 3.202 | 0.2314 | 1.5873 | -1.9625 |
| NPM(%) | 19.06 | 17.77 | 12.2 | 6.48 | 7.02 |
| Revenue | 35.3147 | 28.8895 | 16.2551 | 10.9206 | 10.1475 |
| Expenses | 24.4124 | 21.2376 | 13.1058 | 9.4956 | 8.9294 |
| ROE(%) | 20.48 | 15.62 | 6.03 | 2.15 | 2.16 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Avience Biomedicals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 860.45 | 1.00 | 21.76 | 0.00 | -26.19 | 0.58 |
| Lotus Eye Hospital and Institute Ltd | 114.94 | 3.93 | 1642.00 | 0.00 | 0.39 | 0.00 |
| Vaishali Pharma Ltd | 8.68 | -3.77 | 27.13 | 0.00 | 15.42 | 0.00 |
| Astec Lifesciences Ltd | 661.95 | -1.74 | 0.00 | 0.00 | -363.14 | 0.00 |
Company Info
Our Company was incorporated as Avience Biomedicals Private Limited under the provisions of the Companies Act, 2013 vide certificate of incorporation dated December 23,2019, in Delhi. Subsequently, our Company was converted into a Public Limited Company pursuant to shareholders resolution passed at the Extra Ordinary General Meeting of the Company held on June 26, 2024 and the name of our Company was changed from "Avience Biomedicals Private Limited" to "Avience Biomedicals Limited" vide a fresh Certificate of Incorporation dated September 03,2024 having CIN U74999DL2019PLC359158 issued by the Registrar of Companies, Central Processing Centre, Delhi. The registered office of our company is situated at C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India.MAJOR EVENTS AND MILESTONES:2022- Inauguration of Noida FactoryA new production facility was established in Noida during the pandemic to support the country in its fight against COVID-19.- Initiated E-Commerce Sales through Government e-Marketplace (GeM) OEMWe were certified as an OEM in GeM and started our e-commerce operations as a result.2023- Tenfold increase in turnover during FY 2021-22We achieved an approximately tenfold growth in turnover in FY 2021-22. In FY 2020-21, the turnover was ?113.30 lakhs, which increased to ?1,014.75 lakhs year over year.- New Manufacturing LicensesWe obtained four manufacturing licenses in FY 2021-22 which are as follows:1. Viral Transport Pack2. Pregnancy Card Pregnancy3. Strips Covid 194. RT PCR Assay2022- New Manufacturing LicensesIn FY 2022-23, we received approval for 10 additional production licenses2023- Allotment of landWe secured an allotment of commercial land measuring 2,100 square meters within the Medical Device Park, located in the Yamuna Expressway Industrial Development Area, at a nominal lease rate. This strategically positioned land offers excellent connectivity to the airport and the expressway, enhancing logistical advantages for operations.- First Export Consignment DispatchedThe first export order has been successfully dispatched in FY 2023-24.- Export Entry into the African Continent - SomaliaThe first export order to Somalia has been successfully completed and Company has entered the African continent.- International Export Registration - EthiopiaWe received approval from the Ethiopian Food and Drug Authority (EFDA) to export our products.- Winning a bid in Andhra Pradesh for ? 82.05 lakhsWe received a large government supply order after winning a bid in Andhra Pradesh for ?82.05/- lakhs.- WHO Good Manufacturing Practice GMP ApprovalThe WHO recognized our manufacturing process as a Good Manufacturing Practice (GMP) for producing quality products that meet international quality standards.- MSME ZED Gold CertificationAs of November 13, 2024, there are only 1515 Zed Gold holders in India, and our company is one of them.- New Manufacturing LicensesIn FY 2023-24, we received approval for 31 new production licenses2024- Laying of the foundation stone for the new factoryLaying the foundation stone for the new large production facility at the Medical Device Park at Yamuna Expressway Industrial Development Area.- Sickle Cell Approval We are one of the few manufacturers in India to receive validation for the sickle cell test from ICMR.- Received the first license for the hematology analyzerWe obtained our first license for manufacturing hematology equipment in FY 2024-25.- Conversion of companyTransitioned to a public company, marking a significant milestone in our growth and expansion.- New Manufacturing LicensesIn FY 2024-25, we received approval for 32 new production licenses2025New Manufacturing LicensesIn FY 2025-26, we received approval for 11 new production licenses2026New Manufacturing LicensesIn FY 2025-26, we received approval for 10 new production licenses
Our Company was incorporated as Avience Biomedicals Private Limited under the provisions of the Companies Act, 2013 vide certificate of incorporation dated December 23,2019, in Delhi. Subsequently, our Company was converted into a Public Limited Company pursuant to shareholders resolution passed at the Extra Ordinary General Meeting of the Company held on June 26, 2024 and the name of our Company was changed from "Avience Biomedicals Private Limited" to "Avience Biomedicals Limited" vide a fresh Certificate of Incorporation dated September 03,2024 having CIN U74999DL2019PLC359158 issued by the Registrar of Companies, Central Processing Centre, Delhi. The registered office of our company is situated at C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India.MAJOR EVENTS AND MILESTONES:2022- Inauguration of Noida FactoryA new production facility was established in Noida during the pandemic to support the country in its fight against COVID-19.- Initiated E-Commerce Sales through Government e-Marketplace (GeM) OEMWe were certified as an OEM in GeM and started our e-commerce operations as a result.2023- Tenfold increase in turnover during FY 2021-22We achieved an approximately tenfold growth in turnover in FY 2021-22. In FY 2020-21, the turnover was ?113.30 lakhs, which increased to ?1,014.75 lakhs year over year.- New Manufacturing LicensesWe obtained four manufacturing licenses in FY 2021-22 which are as follows:1. Viral Transport Pack2. Pregnancy Card Pregnancy3. Strips Covid 194. RT PCR Assay2022- New Manufacturing LicensesIn FY 2022-23, we received approval for 10 additional production licenses2023- Allotment of landWe secured an allotment of commercial land measuring 2,100 square meters within the Medical Device Park, located in the Yamuna Expressway Industrial Development Area, at a nominal lease rate. This strategically positioned land offers excellent connectivity to the airport and the expressway, enhancing logistical advantages for operations.- First Export Consignment DispatchedThe first export order has been successfully dispatched in FY 2023-24.- Export Entry into the African Continent - SomaliaThe first export order to Somalia has been successfully completed and Company has entered the African continent.- International Export Registration - EthiopiaWe received approval from the Ethiopian Food and Drug Authority (EFDA) to export our products.- Winning a bid in Andhra Pradesh for ? 82.05 lakhsWe received a large government supply order after winning a bid in Andhra Pradesh for ?82.05/- lakhs.- WHO Good Manufacturing Practice GMP ApprovalThe WHO recognized our manufacturing process as a Good Manufacturing Practice (GMP) for producing quality products that meet international quality standards.- MSME ZED Gold CertificationAs of November 13, 2024, there are only 1515 Zed Gold holders in India, and our company is one of them.- New Manufacturing LicensesIn FY 2023-24, we received approval for 31 new production licenses2024- Laying of the foundation stone for the new factoryLaying the foundation stone for the new large production facility at the Medical Device Park at Yamuna Expressway Industrial Development Area.- Sickle Cell Approval We are one of the few manufacturers in India to receive validation for the sickle cell test from ICMR.- Received the first license for the hematology analyzerWe obtained our first license for manufacturing hematology equipment in FY 2024-25.- Conversion of companyTransitioned to a public company, marking a significant milestone in our growth and expansion.- New Manufacturing LicensesIn FY 2024-25, we received approval for 32 new production licenses2025New Manufacturing LicensesIn FY 2025-26, we received approval for 11 new production licenses2026New Manufacturing LicensesIn FY 2025-26, we received approval for 10 new production licenses
Read More
Parent Organisation
Avience Biomedicals Ltd.
Founded
23/12/2019
Managing Director
Mr.Dharam Deo Choudhary
NSE Symbol
AVIENCESM
FAQ
The current price of Avience Biomedicals Ltd is
The 52-week high for Avience Biomedicals Ltd is
The market capitalization of Avience Biomedicals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Avience Biomedicals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Avience Biomedicals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Avience Biomedicals Ltd shares.
The CEO of Avience Biomedicals Ltd is Mr.Dharam Deo Choudhary, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.